Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of tabelecleucel (Pierre Fabre) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
